Open AccessThe First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
Author(s) -
Satoshi Tanida,
Tsutomu Mizoshita,
Keiji Ozeki,
Hironobu Tsukamoto,
Yoshinori Mori,
Eiji Kubota,
Hiromi Kataoka,
Toshio Kamiya,
Takashi Joh
Publication year - 2014
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr1991w
Subject(s) - medicine , discontinuation , ulcerative colitis , refractory (planetary science) , adalimumab , complete remission , maintenance therapy , vedolizumab , surgery , spontaneous remission , infliximab , gastroenterology , chemotherapy , disease , pathology , physics , astrobiology , alternative medicine
A 43-year-old woman, diagnosed with ulcerative colitis (UC) at age of 30, received outpatient treatment with corticosteroids. However, flare-up occurred, and adalimumab (ADA) treatment commenced in July 2009. A complete remission with mucosal healing was achieved by 32 weeks after initiation of ADA therapy. Because of progressive skin eruptions, ADA maintenance was discontinued at 124 weeks. Regardless, complete remission with mucosal healing was maintained until 176 weeks. We concluded that ADA is an effective therapy to achieve a complete remission in a patient with steroid-refractory UC, and that long-term complete remission may be an important indication to discontinue biological therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom